FDA Clearance Tracker · P130009-S002
EDWARDS SAPIEN XT TRANSCATHETER HEART VALVE AND ACCESSORIES
Last checked: Nov 20, 2026Latest source record: Sep 12, 2014 (this decision)Source: openFDAMethods & limitations
Decided
Sep 12, 2014
Approved
Time to decision
60 days
Received Jul 14, 2014. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P130009-S002
- Device name
- EDWARDS SAPIEN XT TRANSCATHETER HEART VALVE AND ACCESSORIES
- Applicant
- Edwards Lifesciences, LLC
- Applicant location
- Irvine, CA
- Received
- Jul 14, 2014
- Decided
- Sep 12, 2014
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol - OSB
- Original approval
- P130009
Device type
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
APPROVAL OF THE POST-APPROVAL STUDY PROTOCOL.
Source documents
Other decisions for Edwards Lifesciences, LLC
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- PASCAL Precision Transcatheter Valve Repair SystemPMA supplement
P220003-S029 · Decided Oct 20, 2026 · 180 days after receipt · Panel Track
Device type: Tricuspid valve repair device, percutaneously delivered (NPS) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.